Ostoros Gyula, Döme Balázs
Országos Korányi Tbc és Pulmonológiai Intézet, Budapest, 1529, Hungary.
Magy Onkol. 2006;50(3):237-41. Epub 2006 Nov 12.
Because erlotinib, an epidermal growth factor receptor tyrosine kinase (EGFRTK) inhibitor, has been shown to be effective and well-tolerated as a second/third-line treatment in the therapy of advanced non-small cell lung cancer (NSCLC), this agent has been recently approved for human NSCLC therapy in the European Union. Although additive and synergistic effects of erlotinib and conventional chemotherapy were demonstrated in the combined regime preclinically, this has yet to be approved in the clinic. Since erlotinib and cytotoxic drugs have different biological targets, they have distinct side effects as well: erlotinib has no toxic effect on the bone marrow, but can cause diarrhea and rash, the latter being thought to be an indicator of the therapeutic efficacy. Several ongoing clinical trials are investigating the potential role of erlotinib in different settings in human NSCLC. This review intends to integrate our current knowledge on the erlotinib treatment in NSCLC.
表皮生长因子受体酪氨酸激酶（EGFRTK）抑制剂厄洛替尼已被证明作为晚期非小细胞肺癌（NSCLC）二线/三线治疗有效且耐受性良好，因此该药物最近在欧盟被批准用于人类NSCLC治疗。尽管在临床前联合治疗方案中已证明厄洛替尼与传统化疗具有相加和协同作用，但尚未在临床上得到批准。由于厄洛替尼和细胞毒性药物具有不同的生物学靶点，它们也有不同的副作用：厄洛替尼对骨髓没有毒性作用，但可引起腹泻和皮疹，后者被认为是治疗效果的一个指标。目前正在进行的几项临床试验正在研究厄洛替尼在人类NSCLC不同治疗环境中的潜在作用。本综述旨在整合我们目前关于NSCLC中厄洛替尼治疗的知识。
